|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen Z, Fillmore CM, Hammerman PS, Kim CF
and Wong KK: Non-small-cell lung cancers: A heterogeneous set of
diseases. Nat Rev Cancer. 14:535–546. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hirsch FR, Scagliotti GV, Mulshine JL,
Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current
therapies and new targeted treatments. Lancet. 389:299–311. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cipriano R, Bryson BL, Miskimen KL, Bartel
CA, Hernandez-Sanchez W, Bruntz RC, Scott SA, Lindsley CW, Brown HA
and Jackson MW: Hyperactivation of EGFR and downstream effector
phospholipase D1 by oncogenic FAM83B. Oncogene. 33:3298–3306. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cipriano R, Miskimen KL, Bryson BL, Foy
CR, Bartel CA and Jackson MW: Conserved oncogenic behavior of the
FAM83 family regulates MAPK signaling in human cancer. Mol Cancer
Res. 12:1156–1165. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bartel CA, Parameswaran N, Cipriano R and
Jackson MW: FAM83 proteins: Fostering new interactions to drive
oncogenic signaling and therapeutic resistance. Oncotarget.
7:52597–52612. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Iyer MK, Niknafs YS, Malik R, Singhal U,
Sahu A, Hosono Y, Barrette TR, Prensner JR, Evans JR, Zhao S, et
al: The landscape of long noncoding RNAs in the human
transcriptome. Nat Genet. 47:199–208. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mercer TR, Dinger ME and Mattick JS: Long
non-coding RNAs: Insights into functions. Nat Rev Genet.
10:155–159. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Blokhin I, Khorkova O, Hsiao J and
Wahlestedt C: Developments in lncRNA drug discovery: Where are we
heading? Expert Opin Drug Discov. 13:837–849. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lin C and Yang L: Long noncoding RNA in
cancer: Wiring signaling circuitry. Trends Cell Biol. 28:287–301.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jiang MC, Ni JJ, Cui WY, Wang BY and Zhuo
W: Emerging roles of lncRNA in cancer and therapeutic
opportunities. Am J Cancer Res. 9:1354–1366. 2019.PubMed/NCBI
|
|
12
|
Huang DW, Sherman BT, Tan Q, Kir J, Liu D,
Bryant D, Guo Y, Stephens R, Baseler MW, Lane HC and Lempicki RA:
DAVID bioinformatics resources: Expanded annotation database and
novel algorithms to better extract biology from large gene lists.
Nucleic Acids Res. 35:W169–W175. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Braschi B, Denny P, Gray K, Jones T, Seal
R, Tweedie S, Yates B and Bruford E: Genenames.org: The HGNC and
VGNC resources in 2019. Nucleic Acids Res. 47:D786–D792. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Paraskevopoulou MD, Vlachos IS, Karagkouni
D, Georgakilas G, Kanellos I, Vergoulis T, Zagganas K, Tsanakas P,
Floros E, Dalamagas T and Hatzigeorgiou AG: DIANA-LncBase v2:
Indexing microRNA targets on non-coding transcripts. Nucleic Acids
Res. 44:D231–D238. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li JH, Liu S, Zhou H, Qu LH and Yang JH:
starBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA
interaction networks from large-scale CLIP-Seq data. Nucleic Acids
Res. 42:D92–D97. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sun H, Liu K, Huang J, Sun Q, Shao C, Luo
J, Xu L, Shen Y and Ren B: FAM111B, a direct target of p53,
promotes the malignant process of lung adenocarcinoma. Onco Targets
Ther. 12:2829–2842. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
He J and Yu J: Long noncoding RNA
FAM83A-AS1 facilitates hepatocellular carcinoma progression by
binding with NOP58 to enhance the mRNA stability of FAM83A. Biosci
Rep. 39:BSR201925502019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang GM, Zang HL, Geng YX and Li YH:
LncRNA FAM83A-AS1 aggravates the malignant development of
esophageal cancer by binding to miR-495-3p. Eur Rev Med Pharmacol
Sci. 24:9408–9415. 2020.PubMed/NCBI
|
|
21
|
Wu F, Zhong Y, Lang XB, Tu YL and Sun SF:
MNX1-AS1 accelerates the epithelial-mesenchymal transition in
osteosarcoma cells by activating MNX1 as a functional oncogene. Eur
Rev Med Pharmacol Sci. 23:8194–8202. 2019.PubMed/NCBI
|
|
22
|
Sun J, Wang X, Fu C, Wang X, Zou J, Hua H
and Bi Z: Long noncoding RNA FGFR3-AS1 promotes osteosarcoma growth
through regulating its natural antisense transcript FGFR3. Mol Biol
Rep. 43:427–436. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu LM, Wu SG, Chen F, Wu Q, Wu CM, Kang
CM, He X, Zhang RY, Lu ZF, Li XH, et al: Atorvastatin inhibits
pyroptosis through the lncRNA NEXN-AS1/NEXN pathway in human
vascular endothelial cells. Atherosclerosis. 293:26–34. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bi X, Guo XH, Mo BY, Wang ML, Luo XQ, Chen
YX, Liu F, Olsen N, Pan YF and Zheng SG: LncRNA PICSAR promotes
cell proliferation, migration and invasion of fibroblast-like
synoviocytes by sponging miRNA-4701-5p in rheumatoid arthritis.
EBioMedicine. 50:408–420. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kong X, Duan Y, Sang Y, Li Y, Zhang H,
Liang Y, Liu Y, Zhang N and Yang Q: LncRNA-CDC6 promotes breast
cancer progression and function as ceRNA to target CDC6 by sponging
microRNA-215. J Cell Physiol. 234:9105–9117. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu F, Zha G, Wu Y, Cai W and Ao J:
Overexpressing lncRNA SNHG16 inhibited HCC proliferation and
chemoresistance by functionally sponging hsa-miR-93. Onco Targets
Ther. 11:8855–8863. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hoffman PC, Mauer AM and Vokes EE: Lung
cancer. Lancet. 355:479–485. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bozatzi P and Sapkota GP: The FAM83 family
of proteins: From pseudo-PLDs to anchors for CK1 isoforms. Biochem
Soc Trans. 46:761–771. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Snijders AM, Lee SY, Hang B, Hao W and
Bissel MJ: FAM83 family oncogenes are broadly involved in human
cancers: An integrative multi-omics approach. Mol Oncol.
11:167–179. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lin Q, Chen H, Zhang M, Xiong H and Jiang
Q: Knocking down FAM83B inhibits endometrial cancer cell
proliferation and metastasis by silencing the PI3K/AKT/mTOR
pathway. Biomed Pharmacother. 115:1089392019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu X, Gao H, Zhang J and Xue D: FAM83D is
associated with gender, AJCC stage, overall survival and
disease-free survival in hepatocellular carcinoma. Biosci Rep.
39:BSR201816402019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim KM, Hussein UK, Park SH, Park SH, Kang
MA, Moon YJ, Zhang Z, Song Y, Park HS, Bae JS, et al: FAM83H is
involved in stabilization of β-catenin and progression of
osteosarcomas. J Exp Clin Cancer Res. 38:2672019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lee SY, Meier R, Furuta S, Lenburg ME,
Kenny PA, Xu R and Bissell MJ: FAM83A confers EGFR-TKI resistance
in breast cancer cells and in mice. J Clin Invest. 122:3211–3220.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Parameswaran N, Bartel CA,
Hernandez-Sanchez W, Miskimen KL, Smigiel JM, Khalil AM and Jackson
MW: A FAM83A positive feed-back loop drives survival and
tumorigenicity of pancreatic ductal adenocarcinomas. Sci Rep.
9:133962019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Peng WX, Koirala P and Mo YY:
LncRNA-Mediated regulation of cell signaling in cancer. Oncogene.
36:5661–5667. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Balbin OA, Malik R, Dhanasekaran SM,
Prensner JR, Cao X, Wu YM, Robinson D, Wang R, Chen G, Beer DG, et
al: The landscape of antisense gene expression in human cancers.
Genome Res. 25:1068–1079. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wanowska E, Kubiak MR, Rosikiewicz W,
Makałowska I and Szcześniak MW: Natural antisense transcripts in
diseases: From modes of action to targeted therapies. Wiley
Interdiscip Rev RNA. 9:e14612018. View Article : Google Scholar
|
|
38
|
Wahlestedt C: Targeting long non-coding
RNA to therapeutically upregulate gene expression. Nat Rev Drug
Discov. 12:433–446. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shi R, Jiao Z, Yu A and Wang T: Long
noncoding antisense RNA FAM83A-AS1 promotes lung cancer cell
progression by increasing FAM83A. J Cell Biochem. 120:10505–10512.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xiao G, Wang P, Zheng X, Liu D and Sun X:
FAM83A-AS1 promotes lung adenocarcinoma cell migration and invasion
by targeting miR-150-5p and modifying MMP14. Cell Cycle.
18:2972–2985. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Pelechano V and Steinmetz LM: Gene
regulation by antisense transcription. Nat Rev Genet. 14:880–893.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Han X, Huang S, Xue P, Fu J, Liu L, Zhang
C, Yang L, Xia L, Sun L, Huang SK and Zhou Y: LncRNA PTPRE-AS1
modulates M2 macrophage activation and inflammatory diseases by
epigenetic promotion of PTPRE. Sci Adv. 5:eaax92302019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chang H, Li B, Zhang X and Meng X:
NCK1-AS1 promotes NCK1 expression to facilitate tumorigenesis and
chemo-resistance in ovarian cancer. Biochem Biophys Res Commun.
5:292–299. 2020. View Article : Google Scholar
|
|
44
|
Zhao Y, Liu Y, Lin L, Huang Q, He W, Zhang
S, Dong S, Wen Z, Rao J, Liao W and Shi M: The lncRNA MACC1-AS1
promotes gastric cancer cell metabolic plasticity via AMPK/Lin28
mediated mRNA stability of MACC1. Mol Cancer. 17:692018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chan JJ and Tay Y: Noncoding RNA:RNA
regulatory networks in cancer. Int J Mol Sci. 19:13102018.
View Article : Google Scholar
|
|
46
|
Zhao G, Zhang L, Qian D, Sun Y and Liu W:
MiR-495-3p inhibits the cell proliferation, invasion and migration
of osteosarcoma by targeting C1q/TNF-related protein 3. Onco
Targets Ther. 12:6133–6143. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Chen S, Wu J, Jiao K, Wu Q, Ma J, Chen D,
Kang J and Zhao G, Shi Y, Fan D and Zhao G: MicroRNA-495-3p
inhibits multidrug resistance by modulating autophagy through
GRP78/mTOR axis in gastric cancer. Cell Death Dis. 9:10702018.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Eun JW, Kim HS, Shen Q, Yang HD, Kim SY,
Yoon JH, Park WS, Lee JY and Nam SW: MicroRNA-495-3p functions as a
tumor suppressor by regulating multiple epigenetic modifiers in
gastric carcinogenesis. J Pathol. 244:107–119. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Halvorsen AR, Sandhu V, Sprauten M, Flote
VG, Kure EH, Brustugun OT and Helland Å: Circulating microRNAs
associated with prolonged overall survival in lung cancer patients
treated with nivolumab. Acta Oncol. 57:1225–1231. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chen X, Xu Y, Liao X, Liao R, Zhang L, Niu
K, Li T, Li D, Chen Z, Duan Y and Sun J: Plasma miRNAs in
predicting radiosensitivity in non-small cell lung cancer. Tumour
Biol. 37:11927–11936. 2016. View Article : Google Scholar : PubMed/NCBI
|
